Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

被引:497
|
作者
Ogitani, Yusuke [1 ]
Hagihara, Katsunobu [2 ]
Oitate, Masataka [2 ]
Naito, Hiroyuki [3 ]
Agatsuma, Toshinori [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Biol & Immunooncol Labs, Tokyo, Japan
[2] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Tokyo, Japan
[3] Daiichi Sankyo Co Ltd, Oncol Labs, Tokyo, Japan
关键词
Antibody-drug conjugate; bystander killing; HER2; T-DM; topoisomerase I inhibitor; BRENTUXIMAB VEDOTIN; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; CATHEPSIN-B; EXPRESSION; LYMPHOMA; THERAPY; PHASE-3; SAFETY;
D O I
10.1111/cas.12966
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window. DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepared using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan derivative (DX-8951 derivative, DXd). It was effective against trastuzumab emtansine (T-DM1)-insensitive patient-derived xenograft models with both high and low HER2 expression. In this study, the bystander killing effect of DS-8201a was evaluated and compared with that of T-DM1. We confirmed that the payload of DS-8201a, DXd (1), was highly membrane-permeable whereas that of T-DM1, Lys-SMCC-DM1, had a low level of permeability. Under a coculture condition of HER2-positive KPL-4 cells and negative MDA-MB-468 cells in vitro, DS-8201a killed both cells, whereas T-DM1 and an antibody-drug conjugate with a low permeable payload, anti-HER2-DXd (2), did not. In vivo evaluation was carried out using mice inoculated with a mixture of HER2-positive NCI-N87 cells and HER2-negative MDA-MB-468-Luc cells by using an in vivo imaging system. In vivo, DS-8201a reduced the luciferase signal of the mice, indicating suppression of the MDA-MB-468-Luc population; however, T-DM1 and anti-HER2-DXd (2) did not. Furthermore, it was confirmed that DS-8201a was not effective against MDA-MB-468-Luc tumors inoculated at the opposite side of the NCI-N87 tumor, suggesting that the bystander killing effect of DS-8201a is observed only in cells neighboring HER2-positive cells, indicating low concern in terms of systemic toxicity. These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1.
引用
收藏
页码:1039 / 1046
页数:8
相关论文
共 50 条
  • [21] Human epidermal growth factor receptor 2 testing recommendation
    Raji, Adekunle
    Lurie, Robert H.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2007, 131 (09) : 1330 - 1331
  • [22] Expression of Human Epidermal Growth Factor Receptor 2 in Meningiomas
    Ramezani, Mazaher
    Firoozabadi, Hanieh
    Rezaei, Mansour
    Khazaei, Sedigheh
    Sadeghi, Masoud
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (01) : 15 - 18
  • [23] Targeting human epidermal growth factor receptor 2: It is time to kill kinase death human epidermal growth factor receptor 3 - Reply
    Attard, Gerhardt
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (17) : 2499 - 2499
  • [24] Doubling Down on Human Epidermal Growth Factor Receptor 2
    Krop, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1574 - 1576
  • [25] Accurate Assessment of Human Epidermal Growth Factor Receptor 2
    Baehner, Frederick L.
    Yoshizawa, Carl
    Shak, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1727 - 1728
  • [26] The biology of human epidermal growth factor receptor 2.
    Sundaresan S.
    Penuel E.
    Sliwkowski M.X.
    Current Oncology Reports, 1999, 1 (1) : 16 - 22
  • [27] Human epidermal growth factor receptor 2 testing recommendation
    Raji, Adekunle
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 4020 - 4021
  • [28] Expression of epidermal growth factor receptor and human epidermal growth factor receptor 2 in periocular squamous cell carcinomas of horses
    Hendrix, Diane V. H.
    Newkirk, Kim M.
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2014, 75 (10) : 912 - 917
  • [29] Epidermal growth factor receptor and human epidermal growth factor receptor 2 gene polymorphisms in endometrial cancer in a Japanese population
    Kitao, Keisuke
    Yoshida, Shigeki
    Kennedy, Stephen
    Takemura, Naoya
    Sugimoto, Makoto
    Deguchi, Masashi
    Ohara, Noriyuki
    Maruo, Takeshi
    REPRODUCTIVE SCIENCES, 2007, 14 (04) : 349 - 357
  • [30] Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Gene Polymorphisms in Endometrial Cancer in a Japanese Population
    Keisuke Kitao
    Shigeki Yoshida
    Stephen Kennedy
    Naoya Takemura
    Makoto Sugimoto
    Masashi Deguchi
    Noriyuki Ohara
    Takeshi Maruo
    Reproductive Sciences, 2007, 14 : 349 - 357